Phase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the ...

Previous trials of neoadjuvant and adjuvant immunotherapy showed clinical benefit in this setting, and perioperative durvalumab combined with neoadjuvant gemcitabine–cisplatin (followed by ...

Durvalumab therapy after chemoradiotherapy significantly improves overall and progression-free survival in patients with limited-stage small cell lung cancer (SCLC). The median overall survival ...

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body ... Parallel Phase III Randomized Trials of Genomic-Risk Stratified ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

In these patients, adding tremelimumab to durvalumab and chemotherapy resulted ... laboratory models and data from the Phase III POSEIDON clinical trial. Initial observations in a clinical cohort ...

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

Clinical trials help to find out if a new treatment or procedure is safe. They also help to find out if it is better than the current treatment or helps you feel better.

Study results, published today in Nature ... laboratory models and data from the Phase III POSEIDON clinical trial. Subscribe to Technology Networks’ daily newsletter, delivering breaking science news ...

Study results, published in Nature ... laboratory models and data from the Phase III POSEIDON clinical trial. Initial ...